Have you been eager to see how HCA Healthcare, Inc . HCA performed in Q1 in comparison with the market expectations?
Let's quickly scan through the key facts from this leading hospital company's earnings release this morning.
Earnings Beat Estimates
HCA Healthcare came out with adjusted earnings per share of $2.33, beating the Zacks Consensus Estimate of $2.07. Earnings shot up nearly 34% year over year.
HCA Healthcare, Inc. Price and EPS Surprise
How Was the Estimate Revision Trend?
You should note that the earnings estimate for HCA Healthcare depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained unchanged at $2.07 per share over the last 7 days.
Revenue Beat Estimates
HCA Healthcare posted revenues of $11.4 billion, beating Zacks Consensus Estimate of $11.3 billion. The reported figure was up from 7.5% from the year-ago quarter.
Key Stats to Note
Adjusted EBITDA totaled $2.1 billion up 5.6% year over year.
Same facility equivalent admissions increased 1.8% year over year, while same facility admissions increased 2.2%. Same facility revenue per equivalent admission increased 3.9%.
Expenses increased nearly 8% year over year to $9.3 billion.
As of Mar 31, 2018, HCA Healthcare operated 178 hospitals and 120 freestanding surgery centers.
The company bought back 4.37 million shares for $423 million.
The expects 2018 revenues in the range of $45 billion-$46 billion, adjusted EBIDTA of $8.45-$8.75 billion, EPS of $8.50-$9.00 and capital expenditures of about $3.5 billion.
What Zacks Rank Says
HCA Healthcare carries a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
Check back later for our full write up on this HCA Healthcare earnings report!
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.